ERBB2 and carcinoma: There are very few clinical data on HER2-targeted therapies for osteosarcoma compared to other carcinomas, due in part to its rarity; in addition, osteosarcoma is predominant in children and young adults, and safety and optimal dosage evaluations for HER2-targeted drugs must be considered separately in the development of such drugs.